Bernard Horowitz, Ph.D., is recognized internationally for his research on blood viral safety and the preparation and characterization of new therapeutics from blood.
He has served on several company scientific advisory boards and as a director of Omrix Therapeutics (a NASDAQ-listed company); Biogentis, Inc.; Dermacor, Inc.; Protein Therapeutics; and V.I. Technologies (VITEX), a company he co-founded and was instrumental in taking public following its spin-out from the New York Blood Center (NYBC). Dr. Horowitz was the NYBC's Vice President for Commercial Development and a Laboratory Head in the NYBC's Lindsley F. Kimball Research Institute. He has served as a scientific consultant to the National Institutes of Health, the Food and Drug Administration, the National Hemophilia Foundation, the International Association of Biological Standardization, and the World Health Organization.
Dr. Horowitz is the recipient of several prestigious awards, including the Robert W. Reilly Leadership Award from the Plasma Protein Therapeutics Association, the Morton Grove Rasmussen Prize from the American Association of Blood Banks, and the 11th International Prix Henri Chaigneau from l'association francaise des hemophiles.
He is a member of the Key Biscayne Green Committee and has served as a director in his local community associations. Dr. Horowitz received his B.S. in Biology from the University of Chicago and his Ph.D. in biochemistry from Cornell University Medical College.
© 2015 The CLEO Institute. All rights reserved.